Contribute Try STAT+ Today

Two patients with advanced Hodgkin lymphoma were told their tumors were so resistant to treatment that hospice was their best option. Then, they were enrolled in a clinical trial of a novel immunotherapy involving so-called natural killer cells. After treatment, they saw complete remission.

Researchers say the results, detailed in data released Friday, are a hopeful if preliminary sign of the potential of immunotherapies harnessing natural killer, or NK, cells — innate immune system cells that have certain advantages over the more commonly recognized adaptive T cell cancer therapies.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.